ZYDUS LIFESCIENCES | TTK HEALTHCARE | ZYDUS LIFESCIENCES/ TTK HEALTHCARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 16.2 | 25.3 | 64.0% | View Chart |
P/BV | x | 2.9 | 3.5 | 82.1% | View Chart |
Dividend Yield | % | 0.9 | 0.8 | 116.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ZYDUS LIFESCIENCES Mar-21 |
TTK HEALTHCARE Mar-21 |
ZYDUS LIFESCIENCES/ TTK HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 509 | 670 | 76.0% | |
Low | Rs | 259 | 313 | 82.6% | |
Sales per share (Unadj.) | Rs | 147.5 | 450.5 | 32.7% | |
Earnings per share (Unadj.) | Rs | 20.9 | 32.9 | 63.5% | |
Cash flow per share (Unadj.) | Rs | 28.0 | 42.6 | 65.7% | |
Dividends per share (Unadj.) | Rs | 3.50 | 6.00 | 58.3% | |
Avg Dividend yield | % | 0.9 | 1.2 | 74.7% | |
Book value per share (Unadj.) | Rs | 126.9 | 208.5 | 60.9% | |
Shares outstanding (eoy) | m | 1,023.74 | 14.13 | 7,245.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.6 | 1.1 | 238.6% | |
Avg P/E ratio | x | 18.4 | 15.0 | 123.0% | |
P/CF ratio (eoy) | x | 13.7 | 11.5 | 118.9% | |
Price / Book Value ratio | x | 3.0 | 2.4 | 128.4% | |
Dividend payout | % | 16.8 | 18.3 | 91.8% | |
Avg Mkt Cap | Rs m | 393,092 | 6,945 | 5,660.0% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 22,548 | 1,601 | 1,408.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 151,022 | 6,365 | 2,372.6% | |
Other income | Rs m | 449 | 100 | 449.0% | |
Total revenues | Rs m | 151,471 | 6,465 | 2,342.8% | |
Gross profit | Rs m | 31,335 | 430 | 7,289.4% | |
Depreciation | Rs m | 7,248 | 137 | 5,286.3% | |
Interest | Rs m | 1,688 | 22 | 7,589.9% | |
Profit before tax | Rs m | 22,848 | 371 | 6,166.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,472 | -94 | -1,567.8% | |
Profit after tax | Rs m | 21,376 | 464 | 4,602.8% | |
Gross profit margin | % | 20.7 | 6.8 | 307.2% | |
Effective tax rate | % | 6.4 | -25.3 | -25.4% | |
Net profit margin | % | 14.2 | 7.3 | 194.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,160 | 3,752 | 2,322.7% | |
Current liabilities | Rs m | 78,613 | 1,888 | 4,164.6% | |
Net working cap to sales | % | 5.7 | 29.3 | 19.3% | |
Current ratio | x | 1.1 | 2.0 | 55.8% | |
Inventory Days | Days | 33 | 15 | 216.7% | |
Debtors Days | Days | 76 | 343 | 22.1% | |
Net fixed assets | Rs m | 140,943 | 1,126 | 12,520.0% | |
Share capital | Rs m | 1,024 | 141 | 724.7% | |
"Free" reserves | Rs m | 128,899 | 2,805 | 4,595.1% | |
Net worth | Rs m | 129,923 | 2,946 | 4,409.5% | |
Long term debt | Rs m | 6,095 | 0 | - | |
Total assets | Rs m | 228,103 | 4,878 | 4,676.0% | |
Interest coverage | x | 14.5 | 17.7 | 82.3% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.7 | 1.3 | 50.7% | |
Return on assets | % | 10.1 | 10.0 | 101.4% | |
Return on equity | % | 16.5 | 15.8 | 104.4% | |
Return on capital | % | 18.0 | 13.3 | 135.3% | |
Exports to sales | % | 0 | 5.0 | 0.0% | |
Imports to sales | % | 10.5 | 0.4 | 2,883.2% | |
Exports (fob) | Rs m | NA | 318 | 0.0% | |
Imports (cif) | Rs m | 15,911 | 23 | 68,405.0% | |
Fx inflow | Rs m | 63,535 | 318 | 20,004.1% | |
Fx outflow | Rs m | 15,911 | 41 | 39,026.2% | |
Net fx | Rs m | 47,624 | 277 | 17,202.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 32,930 | 964 | 3,415.2% | |
From Investments | Rs m | -7,225 | -772 | 935.4% | |
From Financial Activity | Rs m | -25,489 | -172 | 14,857.2% | |
Net Cashflow | Rs m | -905 | 20 | -4,466.9% |
Indian Promoters | % | 74.9 | 74.6 | 100.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 15.4 | 4.8 | 321.7% | |
FIIs | % | 2.5 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 25.1 | 25.4 | 98.7% | |
Shareholders | 408,017 | 15,817 | 2,579.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ZYDUS LIFESCIENCES With: CIPLA SUN PHARMA LUPIN DR. REDDYS LAB AUROBINDO PHARMA
Indian share markets ended on a negative note today as global cues remained weak.
A look into the company's quarter four financial performance.
These companies are likely to benefit the most from Covid-19 vaccines.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More